ThinkData Podcast

Today I’m joined by Jason Li, CTO at Laurel.
Jason previously served as CTO at Ironclad, where he spent nearly a decade building contracting software, and also held engineering leadership roles at SalesforceIQ and Grovo.
Laurel is a Series C AI-powered time intelligence platform for professional services firms, automatically capturing how professionals spend their time and transforming that data into actionable insights that improve efficiency and profitability.
In this episode, we discuss:
• Why most firms still struggle to measure real AI ROI
• The hidden inefficiencies in how professional services firms track time
• What it actually takes to build reliable AI systems inside complex legacy environments
• The biggest mistakes organisations make when adopting AI tools
• How engineering teams are evolving in an AI-first world
If you’re building, buying, or deploying AI inside large organisations, this episode is packed with practical insight.

In this episode of ThinkData, Loren Larsen, CEO and Co-Founder of Videra Health, joins us to explore how AI is being applied in behavioral health beyond chatbots.
Videra’s platform analyzes video, audio, and text to help clinicians detect and monitor mental health risk between visits, enabling earlier intervention and better outcomes without disrupting workflows.
We discuss ROI, responsible growth, the future of AI in healthcare, and what most people misunderstand about behavioral health innovation.

Today’s guest is Sandeep Chinchali, Chief Scientist at Poseidon, a company building the data layer AI actually needs to improve.
While most of the industry obsesses over bigger models and more compute, Poseidon is tackling the real bottleneck: access to rare, high-quality, IP-safe data that can’t be scraped, copied, or faked.
With billions being poured into data centres and revenue growth starting to slow across parts of the AI ecosystem, are we heading for an industry shake-out?
In this episode, we unpack:
• Why more leaders believe the future of AI won’t live solely in hyperscale data centres
• Whether the cloud-only AI model is starting to fracture
• What “edge AI” actually means for real businesses
• Why data quality and trust now matter more than raw volume
• Why scraped internet data is no longer enough
• What executives should truly be paying attention to over the next 3–5 years
• What will separate AI winners from the hype
This is a must-listen for founders, investors, operators, and anyone trying to understand where AI is really heading next.

AI is everywhere in biotech, but where does it genuinely create impact?
In this episode of the ThinkData Podcast, I sat down with Josh Haimson, Co-Founder and CEO of Inductive Bio, to explore how AI-driven virtual chemistry labs are transforming drug discovery.
We cover:
Where AI truly outperforms traditional approaches in drug development
Why computational models are finally earning real trust from scientists
What Inductive Bio’s Series A unlocked, and how they’re balancing speed vs depth
The role of industry partnerships and early adopters in shaping the platform
Where are the biggest AI opportunities in drug discovery over the next 3–5 years

A grounded, technical, and refreshingly honest conversation about the future of AI-powered therapeutics.

Healthcare doesn’t struggle because of a lack of data or innovation.
It struggles because of admin.
In this episode of the ThinkData Podcast, I sit down with Matt Faustmen, Co-Founder and CEO of Honey Health, to explore why back-office operations are the real constraint in modern healthcare, and how autonomous AI agents can finally unblock them.
We talk about:
Why EHR add-ons and traditional automation fall short
How Honey Health decided which customers to go after first, and what they got wrong
What makes AI agents fundamentally different from workflow tools
Where Honey’s real competitive advantage comes from
And the company Matt is actually trying to build over the next five years

This is a grounded, operator-level conversation about building AI for real systems, real constraints, and real outcomes, not demos.
If you’re building in healthtech, AI infrastructure, or regulated industries, this one’s worth your time.